TY - JOUR
T1 - Insight and treatment outcome in obsessive-compulsive disorder
AU - Eisen, Jane L.
AU - Rasmussen, Steven A.
AU - Phillips, Katharine A.
AU - Price, Lawrence H.
AU - Davidson, Jonathan
AU - Lydiard, R. Bruce
AU - Ninan, Philip
AU - Piggott, Teresa
N1 - Funding Information:
Supported by a grant from Pfizer Pharmaceuticals, New York, NY.
PY - 2001
Y1 - 2001
N2 - To determine whether (1) insight in obsessive-compulsive disorder (OCD) improves when OCD symptoms improve, and whether (2) degree of insight in OCD predicts response to sertraline, data were obtained from five sites participating in a larger multisite study of relapse in OCD. During the first 16 weeks of the study, 71 patients received open-label treatment with sertraline and were assessed using the Yale-Brown Obsessive-Compulsive Rating Scale (Y-BOCS) and a rating scale to evaluate insight, the Brown Assessment of Beliefs Scale (BABS), at study baseline and termination. Baseline total BABS score was not significantly correlated with change in Y-BOCS score. Change in BABS total score and change in Y-BOCS total score were significantly correlated. There was no significant difference in mean endpoint Y-BOCS scores for patients with poor insight (n = 14) compared to patients with good insight at baseline (n = 57). Thus, insight improved with decrease in OCD symptom severity. Degree of insight at baseline did not predict response to sertraline, i.e., patients with poor insight were just as likely to respond to sertraline as patients with good insight.
AB - To determine whether (1) insight in obsessive-compulsive disorder (OCD) improves when OCD symptoms improve, and whether (2) degree of insight in OCD predicts response to sertraline, data were obtained from five sites participating in a larger multisite study of relapse in OCD. During the first 16 weeks of the study, 71 patients received open-label treatment with sertraline and were assessed using the Yale-Brown Obsessive-Compulsive Rating Scale (Y-BOCS) and a rating scale to evaluate insight, the Brown Assessment of Beliefs Scale (BABS), at study baseline and termination. Baseline total BABS score was not significantly correlated with change in Y-BOCS score. Change in BABS total score and change in Y-BOCS total score were significantly correlated. There was no significant difference in mean endpoint Y-BOCS scores for patients with poor insight (n = 14) compared to patients with good insight at baseline (n = 57). Thus, insight improved with decrease in OCD symptom severity. Degree of insight at baseline did not predict response to sertraline, i.e., patients with poor insight were just as likely to respond to sertraline as patients with good insight.
UR - http://www.scopus.com/inward/record.url?scp=0035180754&partnerID=8YFLogxK
U2 - 10.1053/comp.2001.27898
DO - 10.1053/comp.2001.27898
M3 - Article
C2 - 11704942
AN - SCOPUS:0035180754
SN - 0010-440X
VL - 42
SP - 494
EP - 497
JO - Comprehensive Psychiatry
JF - Comprehensive Psychiatry
IS - 6
ER -